Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques

16 Mar 2022

Abstract excerpt

Authorized vaccines against SARS-CoV-2 remain less available in low- and middle-income countries due to insufficient supply, high costs, and storage requirements. Global immunity could still benefit from new vaccines using widely available, safe adjuvants, such as alum and protein subunits, suited to low-cost production in existing manufacturing facilities. Here, a clinical-stage vaccine candidate comprising a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to COVID-19 epidemiological studies
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35294244
DOI: 10.1126/sciadv.abl6015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaquesPMID 35294244Read ↗

A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primatesSemantic proximity Read ↗

A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus MacaquesSemantic proximity Read ↗

A recombinant receptor-binding domain in trimeric form generates protective immunity against SARS-CoV-2 infection in nonhuman primatesSemantic proximity Read ↗

saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concernSemantic proximity Read ↗

Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concernSemantic proximity Read ↗

S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primatesSemantic proximity Read ↗

Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concernSemantic proximity Read ↗

Safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152: a phase 1, double-blind, randomised control trialSemantic proximity Read ↗

Efficacy of a stable broadly protective subunit vaccine platform against SARS-CoV-2 variants of concernSemantic proximity Read ↗

Immunogenicity of SARS-CoV-2 vaccine prototype based on virus-like particles of hepatitis B core antigen from genotype G and interleukin 12 expressing Semliki Forest virus as a genetic adjuvant.Semantic proximity Read ↗

Repurposing NASVAC, a hepatitis B therapeutic vaccine, for pre- and postexposure prophylaxis of SARS-CoV-2 infectionSemantic proximity Read ↗

A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.